Pawlak Krystyna, Pawlak Dariusz, Mysliwiec Michal
Department of Nephrology and Clinical Transplantation, Medical University of Bialystok, 14 Zurawia St, 15-540 Bialystok, Poland.
Thromb Res. 2007;119(4):475-80. doi: 10.1016/j.thromres.2006.03.011. Epub 2006 Jul 7.
Elevated levels of soluble urokinase-type plasminogen activator receptor (suPAR) and other fibrinolytic parameters related to the urokinase-type plasminogen activator (uPA) system can be implicated in clot lysis in plasma. In this study, we examined whether the excess suPAR was associated with increased plasma fibrinolytic activity, determined as plasmin/antiplasmin (PAP) complexes in dialysis patients.
Twenty-six patients on maintenance haemodialysis (HD) and 18 on maintenance peritoneal dialysis (CAPD) were examined together with 20 healthy controls. Pre-dialysis blood levels of suPAR, uPA and PAP were determined using commercially ELISA kits.
suPAR, uPA, PAP levels and suPAR/uPA ratio were increased in both groups of dialyzed patients compared to the controls. Moreover, increased suPAR levels directly correlated with those of uPA and PAP (r=0.443 and r=0.393, both p<0.01, respectively); the fibrinolytic markers were also positively associated with each other (r=0.506, p<0.001).
The plasma suPAR antigen levels are significantly increased in uraemic patients undergoing maintenance dialysis compared with healthy volunteers and are closely associated both with uPA as well as PAP. These positive associations suggest a link between suPAR and the fibrinolytic activity in these patients.
可溶性尿激酶型纤溶酶原激活物受体(suPAR)水平升高以及其他与尿激酶型纤溶酶原激活物(uPA)系统相关的纤溶参数可能与血浆中的凝块溶解有关。在本研究中,我们检测了过量的suPAR是否与血浆纤溶活性增加有关,血浆纤溶活性以透析患者的纤溶酶/抗纤溶酶(PAP)复合物来确定。
对26例维持性血液透析(HD)患者、18例维持性腹膜透析(CAPD)患者以及20名健康对照者进行了检测。使用商用ELISA试剂盒测定透析前血液中suPAR、uPA和PAP的水平。
与对照组相比,两组透析患者的suPAR、uPA、PAP水平以及suPAR/uPA比值均升高。此外,suPAR水平升高与uPA和PAP水平直接相关(r分别为0.443和0.393,均p<0.01);纤溶标志物之间也呈正相关(r=0.506,p<0.001)。
与健康志愿者相比,接受维持性透析的尿毒症患者血浆suPAR抗原水平显著升高,且与uPA以及PAP均密切相关。这些正相关表明suPAR与这些患者的纤溶活性之间存在联系。